1. Integration of multiple platforms for the analysis of multifluorescent marking technology applied to pediatric GBM and dipg
- Author
-
Pericoli, G., Petrini, S., Giorda, E., Ferretti, R., Ajmone-Cat, M. A., Court, W., Conti, L. A., De Simone, R., Bencivenga, P., Palma, A., Di Giannatale, A., Jones, C., Carai, A., Mastronuzzi, A., de Billy, E., Locatelli, Franco, Vinci, M., Locatelli F. (ORCID:0000-0002-7976-3654), Pericoli, G., Petrini, S., Giorda, E., Ferretti, R., Ajmone-Cat, M. A., Court, W., Conti, L. A., De Simone, R., Bencivenga, P., Palma, A., Di Giannatale, A., Jones, C., Carai, A., Mastronuzzi, A., de Billy, E., Locatelli, Franco, Vinci, M., and Locatelli F. (ORCID:0000-0002-7976-3654)
- Abstract
The intratumor heterogeneity represents one of the most difficult challenges for the development of effective therapies to treat pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG). These brain tumors are composed of heterogeneous cell subpopulations that coexist and cooperate to build a functional network responsible for their aggressive phenotype. Understanding the cellular and molecular mechanisms sustaining such network will be crucial for the identification of new therapeutic strategies. To study more in-depth these mechanisms, we sought to apply the Multifluorescent Marking Technology. We generated multifluorescent pGBM and DIPG bulk cell lines randomly expressing six different fluorescent proteins and from which we derived stable optical barcoded single cell-derived clones. In this study, we focused on the application of the Multifluorescent Marking Technology in 2D and 3D in vitro/ex vivo culture systems. We discuss how we integrated different multimodal fluorescence analysis platforms, identifying their strengths and limitations, to establish the tools that will enable further studies on the intratumor heterogeneity and interclonal interactions in pGBM and DIPG.
- Published
- 2020